Compugen (Tel Aviv, Israel) reported the discovery and experimental confirmation of a genetic biomarker, CGEN-40001 for predisposition to Type 2 diabetes, using its GeneVa platform, which consists of an in silico database of roughly 350,000 predicted genetic variations in the human genome, with each predicted variation consisting of multiple consecutive nucleotides. (Medical Device Daily)

Boston Scientific (Natick, Massachusetts) has agreed to pay $296 million on behalf of its Guidant subsidiary to settle an investigation with the Department of Justice. (Medical Device Daily)

LenSar (New York), a startup company, says it is developing a new laser therapy that could potentially remove cataracts from people's eyes more efficiently and with greater precision than the current technology used to treat cataracts. The company presented the technology at the recent American Academy of Ophthalmology (San Francisco) meeting. (Medical Device Daily)

SynCardia (Tucson, Arizona), maker of the temporary CardioWest Total Artifical Heart, reported that the world's first Total Artificial Heart (TAH) to dual heart and liver transplant was performed at the Cleveland Clinic. (Medical Device Daily)

BSD Medical (Salt Lake City) reported that published study results demonstrated improvement in overall survival, tumor response rates, and local tumor control from the addition of hyperthermia therapy, delivered using the BSD-2000 Hyperthermia System, to the standard treatment regimen for 45 patients with high-risk bladder cancer. (Medical Device Daily)